期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HER-2在上皮性卵巢癌组织的表达及其临床意义

Expression and clinical significance of HER-2 in epithelial ovarian cancer
下载PDF
导出
摘要 目的:研究HER-2在上皮性卵巢癌组织、卵巢良性肿瘤及正常卵巢组织的表达及其临床意义,为卵巢癌的发病及转移机制提供一定的理论依据。方法:应用MaxVision快捷免疫组化法检测27例上皮性卵巢癌、29例卵巢良性肿瘤和32例正常卵巢组织中HER-2的表达情况;并分析HER-2的表达与临床病理特征的关系。结果:HER-2在上皮性卵巢癌组织的阳性表达率明显高于卵巢良性肿瘤组织和正常卵巢组织(P<0.05)。在上皮性卵巢癌组织中,临床分期越晚,病理学分级越高,HER-2的阳性表达率也越高(P<0.05)。结论:HER-2在卵巢癌组织异常表达,与上皮性卵巢癌的恶性程度有关。 Objective ：To study the expressions and clinical significance of HER -2 in epithelial ovarian cancer, ovarian benign tumors and normal ovarian tissue; to provide theoretical basis for ovarian cancer incidence and transfer mechanism. Method ： Immunohistochemisty method of Maxvision was used to detect the HER -2 expression in 27 cases of epithelial ovarian cancer,29 cases of benign epithelial ovarian cancer and 32 cases of normal ovarian tissue. To analysis the relationship between the expression of HER - 2 and clinical features. Results：The positive rate of HER -2 in ovarian cancer was significantly higher than that of ovarian benign and normal tissue （ P 〈 0.05 ）. The HER - 2 positive expression in epithelial ovarian cancer became higher when the clinical period later and the pathology grade worse （P 〈 0.05 ）. Conclusion： HER -2 abnormally expressed in ovarian cancer; it may be related to the degree of malignancy in epithelial ovarian cancer.
作者 陈明芳 汪泉 曹清 徐晓 周燕
机构地区 广东省普宁市中医医院妇产科 江西省九江市妇幼保健院病理科 江西省九江市第三人民医院病理科 江西省九江学院附属医院病理科
出处 《中国民族民间医药》 2009年第16期32-33,共2页 Chinese Journal of Ethnomedicine and Ethnopharmacy
关键词 卵巢癌 癌基因 HER-2 ovarian cancer oncogene HER-2
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Dimova l,Zaharieva B, Baitcheva S,et al. Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors[J].Int J Gynecol Cancer ,2006,16 ( 1 ) : 145 - 51.
  • 2Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HEB2 binding affibody molecule[J].Cancer Res, 2006,15; 66(8) :4339 -48.
  • 3Baspollini MR, Amunni G, Villanucci A, et al. HER -2/neu and bcl - 2 in ovarian carcinoma: clinicopathologic, immunohistochemical,and molecular study in patients with shorter and longer survival [ ]]. Appl Immunohistochem Mol Molphol,2006,14 (2) : 181 - 6.
  • 4Steffen AC, Orlova A, Wikman M, et al. Affibody - mediated tumour targeting of HER -2 expressing xenografts in mice[J]. Eur J Nucl Med Mol Imaging,2006,33 (6) :631 -8.
  • 5Tanabe H, Nishii H, Sakata A, et al, Ovcrexpression of HER - 2/neu is not a risk factor in ovarian clear cell edenocarcinoma[ J]. Gynecol Oncol,2004,94 ( 3 ) :735 - 9.
  • 6Ioachim E, Kitsiou E, Chamlabopoulos K, et al. Immunohistochemical evaluation of cathepsin D in normal, hyperplastic and malignant endometrium: correlation with hormone receptor status c - erbB - 2, p53 ,Rb proteins and proliferation associated indices[J]. Int J Gynecol Cancer,2003,13(3) :344 -51.
  • 7李力,钟艳萍,张玮,张洁清,姚忠强.C-erbB2、C-erbB3、C-erbB4的表达与卵巢恶性肿瘤的关系[J].癌症,2004,23(5):568-572. 被引量：8
  • 8吴永忠,任庆兰,刘宇,陈晓品,李少林.脂质体-c-erbB-2反义寡核苷酸转染对人卵巢癌裸鼠皮下移植瘤形成的抑制作用研究[J].肿瘤防治研究,2003,30(2):85-87. 被引量：2
  • 9zum BUschenfelde CM, Hermann C, et al. Antihuman epidermal growth factor receptor 2 ( HEB2 ) monoclonal antibody trastuzumab enhances cytolytic activity of class I - restricted HEB2 - specific T lymphocytes against HER2 -overexpreesing tumor cells[J]. Cancer Res,2002,62(8) :2244 -7.
  • 10Willim K and Richard SP. DNA damage and cell cycle checkpoints[J].The FASEB J,1996,10:238 -247.

二级参考文献14

  • 1Revillion F,Bonneterre J.ErbB2 oncogene in human breast cancer and its clinical significance [J].Eur J Cancer,1998,34(6):791-808.
  • 2Mandai M,Konishi I,Koshiyama M,et al.Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas:correlation with clinicopathology,EGFR,C-erbB2,and C-erbB3 genes,and sex steroid receptor expression [J].Cancer Res,1994,54(7):1825-1830.
  • 3Gilmour LM,Macleod KG,McCaig A,et al.Expression of erbB4/HER-4 growth factor receptor isoforms in ovarian cancer[J].Cancer Res,2001,61(5):2169-2176.
  • 4Simpson BJ,Phillips HA,Lessells AM,et al.C-erbB growth-factor-receptor proteins in ovarian tumours [J].Int J Cancer,1995,64(3):202-206.
  • 5Skirnisdottir I,Sorbe B,Seidal T.The growth factor receptors HER-2/neu and EGFR,their relationship,and their effects on the prognosis in early stage(FIGO Ⅰ-Ⅱ) epithelial ovarian carcinoma [J].Int J Gynecol Cancer,2001,11(2):119-129.
  • 6Wond YF,Cheung TH,Lam SK,et al.Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer [J].Gynecol Obstet Invest,1995,40(3):209-212.
  • 7Anreder MB,Freeman SM,Merogi A,et al.p53,C-erbB2,and PCNA statues in benign,proliferative and malignant ovarian surface epithelial neoplasms:a study of 75 cases [J].Arch Pathol Lab Med,1999,123(4):310-316.
  • 8Meden H,Marx D,Roegglen T,et al.Overexpression of the oncogene C-erbB2(HER2/neu) and response to chemotherapy in patients with ovarian cancer [J].Int J Gynecol Pathol,1998,17(1):61-65.
  • 9Kumar R,Yarmand-Bagheri R.The role of HER2 in angiogenesis [J].Semin Oncol,2001,28(5 Suppl 16):27-32.
  • 10Hoar FJ,Chaudhri S,Wadley MS,et al.Co-expression of vascular endothelial growth factor C(VEGF-C) and C-erbB2 in human breast carcinoma [J].Eur J Cancer,2003,39(12):1698-1703.

共引文献8

中国民族民间医药
2009年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部